Pimagedine

Pimagedine, also known as Aminoguanidine, is a diamondoid and an inhibitor of the enzyme inducible Nitric Oxide Synthase (iNOS). It is a drug that was once studied for the treatment of diabetic nephropathy and neuropathy.

History

Pimagedine was developed by Alteon in the 1990s. The drug was initially promising in early trials, but later studies showed that it had no significant benefits over placebo. As a result, development of the drug was discontinued.

Mechanism of action

Pimagedine works by inhibiting the enzyme iNOS. This enzyme is responsible for producing nitric oxide (NO), a molecule that plays a key role in many physiological and pathological processes. By inhibiting iNOS, Pimagedine reduces the production of NO, which can help to prevent or reduce the damage caused by excessive NO production.

Clinical trials

Several clinical trials were conducted to evaluate the efficacy of Pimagedine in treating diabetic nephropathy and neuropathy. However, these trials did not show any significant benefits of the drug over placebo. In addition, some patients experienced side effects such as gastrointestinal disturbances and liver abnormalities.

See also

• Diabetic nephropathy
• Neuropathy
• Nitric oxide synthase
• Alteon (company)

References

• 
  Pimagedine
• 
  Pimagedine
• 
  Pimagedine